Athena Countouriotis
Direktor/Vorstandsmitglied bei BIOMARIN PHARMACEUTICAL INC.
Vermögen: 590 031 $ am 30.04.2024
Profil
Athena Countouriotis ist Mitglied des Vorstands von Iovance Biotherapeutics, Inc. und NuMedii, Inc. sowie Präsidentin, Chief Executive Officer & Director bei Turning Point Therapeutics, Inc. Dr. Countouriotis war zuvor Director-Oncology Global Clinical Research bei Bristol Myers Squibb Co, Chief Medical Officer & Senior Vice President bei Halozyme Therapeutics, Inc, Chief Medical Officer & Senior Vice President bei Adverum Biotechnologies, Inc, Associate Medical Director bei CTI BioPharma Corp. und Chief Medical Officer bei Ambit Biosciences Corp. Dr. Countouriotis promovierte an der Tufts University School of Medicine und erwarb einen Bachelor-Abschluss an der University of California, Los Angeles.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2024 | 6 900 ( 0,00% ) | 566 973 $ | 30.04.2024 | |
PASSAGE BIO, INC.
0,03% | 21.05.2024 | 18 900 ( 0,03% ) | 23 058 $ | 30.04.2024 |
| 17.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Athena Countouriotis
| Unternehmen | Position | Beginn |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.06.2019 |
| PASSAGE BIO, INC. | Direktor/Vorstandsmitglied | 01.02.2020 |
| BIOMARIN PHARMACEUTICAL INC. | Direktor/Vorstandsmitglied | 27.12.2023 |
Avenzo Therapeutics, Inc.
 Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Vorstandsvorsitzender | - |
Capstan Therapeutics, Inc.
 Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Vorsitzender | 12.10.2022 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Vorsitzender | 12.09.2022 |
NuMedii, Inc.
 NuMedii, Inc. Miscellaneous Commercial ServicesCommercial Services NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA. | Direktor/Vorstandsmitglied | 20.06.2018 |
Leal Therapeutics, Inc.
 Leal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Leal Therapeutics, Inc. develops novel therapeutics for patients with major disorders of the central nervous systems. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Athena Countouriotis
| Unternehmen | Position | Ende |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 24.01.2020 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Athena Countouriotis
| University of California, Los Angeles | Undergraduate Degree |
| Tufts University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| CARDIFF ONCOLOGY, INC. | Health Technology |
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
NuMedii, Inc.
NuMedii, Inc. Miscellaneous Commercial ServicesCommercial Services NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA. | Commercial Services |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Commercial Services |
Leal Therapeutics, Inc.
Leal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Leal Therapeutics, Inc. develops novel therapeutics for patients with major disorders of the central nervous systems. | Commercial Services |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Commercial Services |
